Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.

BMC research notes - 25 Jun 2014

Glaysher Sharon, Bolton Louise M, Johnson Penny, Torrance Christopher, Cree Ian A

Abstract excerpt

BACKGROUND: The epidermal growth factor receptor family is expressed in breast cancer, and agents targeting this pathway have single agent effects (e.g. traztuzumab). Development of resistance may be due to the presence of alternative pathways, particularly activation of the PI3K/Akt/MTOR pathway...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast
Share to Drug Synergism
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 24964744
DOI: 10.1186/1756-0500-7-397
PMCID: PMC4080989

Genes

EGFR
MTOR
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24964744-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.PMID 24964744Read ↗

Targeting EGFR and PI3K pathways in ovarian cancerSemantic proximity Read ↗

PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.Semantic proximity Read ↗

Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer LinesSemantic proximity Read ↗

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.Semantic proximity Read ↗

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.Semantic proximity Read ↗

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.Semantic proximity Read ↗

PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.Semantic proximity Read ↗

Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.